Robert Essner Acquires Shares in Organon & Co.
On June 12, 2026, Robert Essner purchased 17,857 shares of Organon & Co. at $13.44 each.
Key Points
- Robert Essner bought 17,857 shares of Organon & Co. on June 12, 2026, at $13.44 per share, totaling $239,998.08.
- Organon & Co. has a market cap of $3.53 billion and a P/E ratio of 14.45, with shares trading near $13.44.
- BlackRock added 751,009 shares of Organon, while LSV Asset Management reduced its stake by 212,699 shares.
On June 12, 2026, Robert Essner purchased 17,857 shares of Organon & Co. (NYSE: OGN) at a price of $13.44 per share. This transaction was valued at $239,998.08 and was not part of a pre-planned trading program.
Other Institutional Activity in Organon & Co.
Institutional investors have also been adjusting their positions in Organon & Co. BlackRock, Inc. increased its holdings by 751,009 shares, bringing its total to 31,717,028 shares worth about $189.98 million. Vanguard Portfolio Management LLC established a new position with 21,846,036 shares valued at approximately $130.86 million. Meanwhile, LSV Asset Management trimmed its stake by 212,699 shares, ending with 7,259,730 shares valued at $43.49 million.
Organon & Co. Stock Snapshot
Shares of NYSE:OGN are trading near $13.44. Organon & Co. has a market capitalization of approximately $3.53 billion and a P/E ratio of 14.45. The company's stock has seen a 52-week low of $5.69 and a high of $13.49, with a 50-day moving average of $11.88 and a 200-day moving average of $9.04. Organon's beta is 1.544, indicating higher volatility compared to the market.
Recent Earnings
Organon & Co. reported revenue of $6.16 billion, though it experienced a slight decline in revenue growth of 3.5%. The company achieved a net margin of 3.99% and a return on equity of 34.05%. Its next earnings report is scheduled for August 4, 2026.
Dividend
Organon & Co. offers an annual dividend rate of $0.08, yielding 0.6% with a payout ratio of 8.6%.
Insider Buying and Selling at Organon & Co.
In addition to Robert Essner, several other insiders purchased 17,857 shares each on June 12, 2026. These insiders include Shalini Sharp, Philip Ozuah, Ramona Sequeira, Deborah Leone, and Alan Ezekowitz, all buying at the same price of $13.44 per share.
Analysts Set New Price Targets
On April 29, 2026, BNP Paribas downgraded Organon & Co. to a 'hold' rating with a price target of $14.00. Piper Sandler upgraded the stock to 'hold' with the same target on April 28, 2026. Barclays maintained a 'sell' rating with an $8.00 target on February 24, 2026. The consensus target price is $11.25, with four analysts providing opinions.
About Organon & Co.
Organon & Co., headquartered in Jersey City, New Jersey, develops women's health solutions and other therapies. The company offers a range of products, including contraceptives like Nexplanon and NuvaRing, fertility treatments, and biosimilars for immunology and oncology. Organon serves various markets globally, including the U.S., Europe, and Asia.
Bottom Line
Robert Essner's recent purchase of Organon & Co. shares highlights ongoing interest in the company. Investors keep an eye on insider transactions for potential signals, though these filings reflect past actions. Organon's diversified health portfolio and global reach make it a company of interest in the healthcare sector.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.